Funding of $16 Million Secured for the Progression of Validation Management in Lifecycle
ValGenesis, a leading provider of digital validation solutions for life sciences, has announced that it has secured up to $16 million in strategic financing. This funding comes from Bridge Bank's Innovation Banking Group and Morgan Stanley Expansion Capital [1].
The new funds will primarily be used to accelerate global expansion and advance product innovation, with a strong focus on artificial intelligence (AI)-powered validation solutions. This move aims to transform compliance management and speed up time to market for life sciences companies [2].
Melissa Daniels, Managing Director at Morgan Stanley Expansion Capital, expressed confidence that the new financing will enable ValGenesis to accelerate global expansion and deepen product innovation. Peter Haman from Bridge Bank's Innovation Banking Group shared similar sentiments, expressing confidence in ValGenesis' potential for accelerated growth and enhanced market presence [3].
ValGenesis' market leadership lies in bringing innovative digital validation solutions to life sciences. The company is known for digitizing and automating validation processes for pharmaceutical, biotech, and medical device organizations [4].
The funding will also support strategic hiring, expanding regional partnerships, and enhancing customer success initiatives across North America, Europe, and Asia-Pacific. This is in response to the growing demand in regulated industries for digital validation solutions [1].
ValGenesis' AI-assisted validation platform is backed by a growing number of issued patents. Recently, the company launched an AI-assisted validation program, which is expected to benefit significantly from this funding [2].
The new financing positions ValGenesis to redefine industry best practices, further solidifying its position as a pioneer in the digital validation space within life sciences. The CEO of ValGenesis expressed confidence that the funding reflects strong support for their vision, innovation, and execution in transforming how life sciences companies manage compliance and accelerate time to market [5].
References: [1] ValGenesis Press Release. (2022). ValGenesis Secures $16 Million in Strategic Financing. Retrieved from https://www.valgenesis.com/news/valgenesis-secures-16-million-in-strategic-financing/ [2] ValGenesis. (2022). ValGenesis Smart GxP. Retrieved from https://www.valgenesis.com/products/valgenesis-smart-gxp/ [3] Morgan Stanley Expansion Capital. (n.d.). About Us. Retrieved from https://www.morganstanley.com/im/en/private-equity/expansion-capital/about-us.html [4] Bridge Bank. (n.d.). Innovation Banking Group. Retrieved from https://www.bridgebank.com/innovation-banking-group/ [5] ValGenesis. (n.d.). About Us. Retrieved from https://www.valgenesis.com/about-us/
The new funds from strategic financing will be utilized for accelerating global expansion, product innovation, and investing in AI-powered validation solutions, his intended to transform compliance management and speed up time to market for life sciences companies. The funding will also support strategic hiring, expanding regional partnerships, and enhancing customer success initiatives across various regions, in response to the growing demand in regulated industries for digital validation solutions.
